Skip to main content

Table 2 Demographic and baseline characteristics (ITT data set)

From: Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study

Characteristic

Placebo

(N = 17)

Fulranumab 9 mg

(N = 14)

Sex, n (%)

  

 Female

13 (76.5)

13 (92.2)

 Male

4 (23.5)

1 (7.1)

Race, n (%)

  

 White

16 (94.1)

13 (92.9)

 Black or African American

1 (5.9)

1 (7.1)

Age (years)

  

 Mean ± SD

46.2 (13.56)

50.6 (10.68)

 Range

25–69

38–78

Body weight (kg)

  

 Mean ± SD

78.9 (16.61)

71.7 (26.12)

 Range

54–117

46–148

UPOINT clinical phenotyping, n (%)

  

 Urinary

17 (100)

14 (100)

 Psychosocial

5 (29)

3 (21)

 Organ-specific

16 (94)

11 (79)

 Infection

4 (24)

5 (36)

 Neurological/systemic

7 (41)

9 (64)

 Tender point

12 (71)

9 (64)

Duration of interstitial cystitis (years)

  

 Mean ± SD

9.4 (9.87)

5.8 (5.44)

 Range

2–40

1–20

Hunner’s ulcer and/or glomerulation, n (%)

  

 Yes

9 (52.9)

10 (71.4)

 No

8 (47.1)

4 (28.6)